18
Special Populations
82. Administer 3 doses of HepB starting at 6-12 months after HSCT
(SR-M). If a postvaccination anti-HBs concentration of ≥10 mIU/mL
is not attained, a second 3-dose series of HepB (SR-L) (Alternative:
1 dose of HepB after which anti-HBs is tested*) using standard
dose (SR-M) or high dose (40 μg)* (WR-L) for children and high
dose for adolescents* and adults (SR-L) should be administered.
83. Administer 3 doses of IPV starting 6-12 months after HSCT (SR-M).
84. Consider administration of 3 doses of HPV starting at 6-12 months
after HSCT for female patients ages 11-26 years and HPV4 in males
ages 11-26 years (WR-VL).
85. Do not administer live vaccines to HSCT patients with active GVHD
or ongoing immunosuppression (SR-L).
86. Administer a 2-dose series of MMR to measles-seronegative
adolescents and adults (SR-L) and to measles-seronegative children
(SR-M) starting 24 months after HSCT in patients with neither
chronic GVHD nor ongoing immunosuppression and 8-11 months
(or earlier if in a measles outbreak situation) after the last dose of
immune globulin intravenous (IGIV).
87. Administer a 2-dose series of VAR starting 24 months after HSCT
to varicella-seronegative patients with neither GVHD nor ongoing
immunosuppression and 8-11 months after the last dose of IGIV
(SR-L).
